Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-007191
Filing Date
2024-02-20
Accepted
2024-02-20 14:39:18
Documents
74
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2320381
2 ex31-1.htm EX-31.1 11068
3 ex32-1.htm EX-32.1 6917
  Complete submission text file 0001493152-24-007191.txt   9925264

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ppcb-20231231.xsd EX-101.SCH 66492
5 XBRL CALCULATION FILE ppcb-20231231_cal.xml EX-101.CAL 68467
6 XBRL DEFINITION FILE ppcb-20231231_def.xml EX-101.DEF 328522
7 XBRL LABEL FILE ppcb-20231231_lab.xml EX-101.LAB 534521
8 XBRL PRESENTATION FILE ppcb-20231231_pre.xml EX-101.PRE 437822
76 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1497503
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-54878 | Film No.: 24652481
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)